Visfatin levels and intima-media thicknesses in rheumatic diseases

Clinical Rheumatology

Volumn 30, Issue 6, 2011, Pages 757-763

  Ozgen, Metin ^a   Koca, Suleyman Serdar ^a   Aksoy, Kader ^a   Dagli, Necati ^a   Ustundag, Bilal ^a   Isik, Ahmet ^a  

^a FIRAT UNIVERSITY   (Turkey)

Author keywords

Chronic inflammation; IMT; Insulin resistance; Visfatin

Indexed keywords

INTERLEUKIN 6; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ARTERIAL WALL THICKNESS; ARTICLE; BEHCET DISEASE; CAROTID ATHEROSCLEROSIS; CONTROLLED STUDY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RHEUMATIC DISEASE; RHEUMATOID ARTHRITIS; SYSTEMIC LUPUS ERYTHEMATOSUS; SYSTEMIC SCLEROSIS;

ADULT; ARTHRITIS, RHEUMATOID; ATHEROSCLEROSIS; BEHCET SYNDROME; BIOLOGICAL MARKERS; FEMALE; HUMANS; INTERLEUKIN-6; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; MIDDLE AGED; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE; PREDICTIVE VALUE OF TESTS; RETROSPECTIVE STUDIES; RISK FACTORS; SCLERODERMA, SYSTEMIC; TH1 CELLS; TH2 CELLS; TUMOR NECROSIS FACTOR-ALPHA; TUNICA INTIMA; TUNICA MEDIA;

EID: 79959611231     PISSN: 07703198     EISSN: 14349949     Source Type: Journal    
DOI: 10.1007/s10067-010-1649-2     Document Type: Article

References (46)

1. Sattar N, McCarey DW, Capell H, McInnes IB (2003) Explaining how "high-grade" systemic inflammation accelerates vascular risk in rheumatoid arthritis. Circulation 108:2957-2963
2. Symmons DP, Jones MA, Scott DL, Prior P (1998) Longterm mortality outcome in patients with rheumatoid arthritis: early presenters continue to do well. J Rheumatol 25:1072-1077 (Pubitemid 28350878)
3. Ward MM (1999) Premature morbidity from cardiovascular and cerebrovascular diseases in women with systemic lupus erythematosus. Arthritis Rheum 42:338-346
4. Thompson T, Sutton-Tyrrell K, Wildman RP et al (2008) Progression of carotid intima-media thickness and plaque in women with systemic lupus erythematosus. Arthritis Rheum 58:835-842 (Pubitemid 351364882)
5. Hettema ME, Zhang D, de Leeuw K et al (2008) Early atherosclerosis in systemic sclerosis and its relation to disease or traditional risk factors. Arthritis Res Ther 10:R49
6. OztürkMA, Oktar SO, Unverdi S et al (2006)Morphologic evidence of subclinical atherosclerosis obtained by carotid ultrasonography in patients with Behcet's disease. Rheumatol Int 26:867-872 (Pubitemid 43962114)
7. Full LE, Ruisanchez C, Monaco C (2009) The inextricable link between atherosclerosis and prototypical inflammatory diseases rheumatoid arthritis and systemic lupus erythematosus. Arthritis Res Ther 11:217
8. Koca SS, Karaca I, Yavuzkir MF et al (2009) Insulin resistance is related with oxidative stress in systemic lupus erythematosus. Anadolu Kardiyol Derg 9:23-28
9. Lang CH, Dobrescu C, Bagby GJ (1992) Tumor necrosis factor impairs insulin action on peripheral glucose disposal and hepatic glucose output. Endocrinology 130:43-52
10. Vozarova B,Weyer C, Hanson K, Tataranni PA, Bogardus C, Pratley RE (2001) Circulating interleukin-6 in relation to adiposity, insulin action, and insulin secretion. Obes Res 9:414-417 (Pubitemid 33603868)
11. Fernández-Real JM, Ricart W (2003) Insulin resistance and chronic cardiovascular inflammatory syndrome. Endocr Rev 24:278-301 (Pubitemid 36724371)
12. Gonzalez-Gay MA, Gonzalez-Juanatey C, Lopez-Diaz MJ et al (2007) HLA-DRB1 and persistent chronic inflammation contribute to cardiovascular events and cardiovascular mortality in patients with rheumatoid arthritis. Arthritis Rheum 57:125-132
13. Samal B, Sun Y, Stearns G, Xie C, Suggs S, McNiece I (1994) Cloning and characterization of the cDNA encoding a novel human pre-B-cell colony-enhancing factor. Mol Cell Biol 14:1431-1437
14. Moschen AR, Kaser A, Enrich B et al (2007) Visfatin, an adipocytokine with proinflammatory and immunomodulating properties. J Immunol 178:1748-1758 (Pubitemid 46154646)
15. Ognjanovic S, Bryant-Greenwood GD (2002) Pre-B-cell colony-enhancing factor, a novel cytokine of human fetal membranes. Am J Obstet Gynecol 187:1051-1058 (Pubitemid 35178410)
16. Jia SH, Li Y, Parodo J et al (2004) Pre-B cell colony-enhancing factor inhibits neutrophil apoptosis in experimental inflammation and clinical sepsis. J Clin Invest 113:1318-1327 (Pubitemid 39069931)
17. Ye SQ, Simon BA, Maloney JP et al (2005) Pre-B cell colony-enhancing factor as a potential novel biomarker in acute lung injury. Am J Respir Crit Care Med 171:361-370 (Pubitemid 40223404)
18. Otero M, Lago R, Gomez R et al (2006) Changes in plasma levels of fat-derived hormones adiponectin, leptin, resistin and visfatin in patients with rheumatoid arthritis. Ann Rheum Dis 65:1198-1201 (Pubitemid 44277396)
19. Fukuhara A, Matsuda M, Nishizawa M et al (2005) Visfatin: a protein secreted by visceral fat that mimics the effects of insulin. Science 307:426-430 (Pubitemid 40139988)
20. Berndt J, Klöting N, Kralisch S et al (2005) Plasma visfatin concentrations and fat depot-specific mRNA expression in humans. Diabetes 54:2911-2916 (Pubitemid 41401086)
21. Chen MP, Chung FM, Chang DM et al (2006) Elevated plasma level of visfatin/pre-B cell colony-enhancing factor in patients with type 2 diabetes mellitus. J Clin Endocrinol Metab 91:295-299
22. Kim SR, Bae YH, Bae SK et al (2008) Visfatin enhances ICAM-1 and VCAM-1 expression through ROS-dependent NF-kappaB activation in endothelial cells. Biochim Biophys Acta 1783:886-895
23. Dahl TB, Yndestad A, Skjelland M et al (2007) Increased expression of visfatin in macrophages of human unstable carotid and coronary atherosclerosis: possible role in inflammation and plaque destabilization. Circulation 115:972-980 (Pubitemid 46328290)
24. Arnett FC, Edworthy SM, Bloch DA et al (1988) The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 31:315-324 (Pubitemid 18091653)
25. Hochberg MC (1997) Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 40:1725
26. LeRoy EC, Medsger TA Jr (2001) Criteria for the classification of early systemic sclerosis. J Rheumatol 28:1573-1576 (Pubitemid 32660630)
27. International Study Group for Behcet's Disease (1990) Criteria for diagnosis of Behcet's disease. Lancet 335:1078-1080
28. Leeb BF, Andel I, Sautner J et al (2005) Disease activity measurement of rheumatoid arthritis: comparison of the simplified disease activity index (SDAI) and the disease activity score including 28 joints (DAS28) in daily routine. Arthritis Rheum 53:56-60 (Pubitemid 40216352)
29. Bombardier C, Gladman DD, Urowitz MB, Caron D, Chang CH (1992) Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE. Arthritis Rheum 35:630-640
30. Gladman D, Ginzler E, Goldsmith C et al (1996) The development and initial validation of the systemic lupus international collaborating clinics/American college of rheumatology damage index for systemic lupus erythematosus. Arthritis Rheum 39:363-369 (Pubitemid 26085211)
31. Della Rossa A, Valentini G, Bombardieri S et al (2001) European multicentre study to define disease activity criteria for systemic sclerosis. I. Clinical and epidemiological features of 290 patients from 19 centres. Ann Rheum Dis 60:585-591
32. Medsger TA Jr, Silman AJ, Steen VD et al (1999) A disease severity scale for systemic sclerosis: development and testing. J Rheumatol 26:2159-2167 (Pubitemid 29487010)
33. Isik A, Koca SS, Ustundag B, Selek S (2007) Decreased total antioxidant response and increased oxidative stress in Behcet's disease. Tohoku J Exp Med 212:133-141 (Pubitemid 47083039)
34. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC (1985) Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28:412-419 (Pubitemid 15018832)
35. Lago F, Dieguez C, Gomez-Reino J, Gualillo O (2007) The emerging role of adipokines as mediators of inflammation and immune responses. Cytokine Growth Factor Rev 18:313-325 (Pubitemid 46891288)
36. Pagano C, Pilon C, Olivieri M et al (2006) Reduced plasma visfatin/pre-B cell colony-enhancing factor in obesity is not related to insulin resistance in humans. J Clin Endocrinol Metab 91:3165-3170 (Pubitemid 44271773)
37. Curat CA, Wegner V, Sengenès C et al (2006) Macrophages in human visceral adipose tissue: increased accumulation in obesity and a source of resistin and visfatin. Diabetologia 49:744-747 (Pubitemid 43357549)
38. Gonzalez-Gay MA, Vazquez-Rodriguez TR, Garcia-Unzueta MT et al (2010) Visfatin is not associated with inflammation or metabolic syndrome in patients with severe rheumatoid arthritis undergoing anti-TNF-alpha therapy. Clin Exp Rheumatol 28:56-62
39. Vadacca M, Margiotta D, Rigon A et al (2009) Adipokines and systemic lupus erythematosus: relationship with metabolic syndrome and cardiovascular disease risk factors. J Rheumatol 36:295-297
40. Brentano F, Schorr O, Ospelt C et al (2007) Pre-B cell colonyenhancing factor/visfatin, a new marker of inflammation in rheumatoid arthritis with proinflammatory and matrix-degrading activities. Arthritis Rheum 56:2829-2839 (Pubitemid 47502729)
41. Lacraz S, Nicod L, Galve-de Rochemonteix B, Baumberger C, Dayer JM, Welgus HG (1992) Suppression of metalloproteinase biosynthesis in human alveolar macrophages by interleukin-4. J Clin Invest 90:382-388
42. Zhang Y, McCluskey K, Fujii K, Wahl LM (1998) Differential regulation of monocyte matrix metalloproteinase and TIMP-1 production by TNF-alpha, granulocyte-macrophage CSF, and IL-1 beta through prostaglandin-dependent and -independent mechanisms. J Immunol 161:3071-3076 (Pubitemid 28425734)
43. Song EK, Lee YR, Yu HN et al (2008) Extracellular NAD is a regulator for FcgammaR-mediated phagocytosis in murine macrophages. Biochem Biophys Res Commun 367:156-161
44. Bogdan C, Vodovotz Y, Nathan C (1991) Macrophage deactivation by interleukin 10. J Exp Med 174:1549-1555
45. Rho YH, Solus J, Sokka T et al (2009) Adipocytokines are associated with radiographic joint damage in rheumatoid arthritis. Arthritis Rheum 60:1906-1914
46. Pay S, Abbasov T, Erdem H et al (2007) Serum MMP-2 and MMP-9 in patients with Behçet's disease: do their higher levels correlate to vasculo-Behçet's disease associated with aneurysm formation? Clin Exp Rheumatol 25:70-75